Granzyme (Gzm) B-deficient mice obtained by gene targeting were used to assess the role of Gzm B in the mechanisms used by natural killer (NK) and lymphokineactivated killer (LAK) and fas-based pathways are the two most important mechanisms used by CTL in mediating cytotoxicity (3-6). In the perforin/Gzm pathway (also known as the granule exocytosis pathway), cytolytic effector cells deliver lethal hits by directionally releasing their granule contents after specific recognition and conjugate formation with a target cell (7, 8). The major granule components involved in this process are the membrane pore-forming protein called perforin and serine proteases termed Gzms (9-13). The pores formed by perforin in the target cell membrane may allow for the entry of Gzms into target cells. Although purified perforin can cause cytolysis under certain conditions, the membrane damage caused by perforin alone does not induce apoptosis, a hallmark of CTL and NK cell attack (14, 15) . Several lines of evidence now favor the Gzms, in particular Gzm A and Gzm B, as the proteins responsible for triggering the target cell "internal disintegration" pathway leading to DNA breakdown and apoptosis (16) (17) (18) (19) (20) (21) (22) (23) . Specifically, studies with the noncytotoxic rat basophilic leukemia (RBL) cells have shown that doubletransfected RBL lines need to express both perforin and Gzm A or B to mediate target cell lysis and DNA damage (20, 21); similarly, purified rat Gzm A has been shown to synergize with purified rat Gzm B to induce DNA fragmentation and apoptosis in permeabilized target cells (17, 18) . Finally, the delivery
Natural killer (NK) cells and cytotoxic T lymphocytes (CTL) are involved in the immune response against viruses and tumors, in graft rejection, in immunopathology, and in various autoimmune diseases (1, 2) . Recent experiments with perforin-deficient and fas receptor (or fas ligand)-deficient mice have demonstrated that the perforin/granzyme (Gzm)-based and fas-based pathways are the two most important mechanisms used by CTL in mediating cytotoxicity (3) (4) (5) (6) . In the perforin/Gzm pathway (also known as the granule exocytosis pathway), cytolytic effector cells deliver lethal hits by directionally releasing their granule contents after specific recognition and conjugate formation with a target cell (7, 8) . The major granule components involved in this process are the membrane pore-forming protein called perforin and serine proteases termed Gzms (9-13). The pores formed by perforin in the target cell membrane may allow for the entry of Gzms into target cells. Although purified perforin can cause cytolysis under certain conditions, the membrane damage caused by perforin alone does not induce apoptosis, a hallmark of CTL and NK cell attack (14, 15) . Several lines of evidence now favor the Gzms, in particular Gzm A and Gzm B, as the proteins responsible for triggering the target cell "internal disintegration" pathway leading to DNA breakdown and apoptosis (16) (17) (18) (19) (20) (21) (22) (23) . Specifically, studies with the noncytotoxic rat basophilic leukemia (RBL) cells have shown that doubletransfected RBL lines need to express both perforin and Gzm A or B to mediate target cell lysis and DNA damage (20, 21) ; similarly, purified rat Gzm A has been shown to synergize with purified rat Gzm B to induce DNA fragmentation and apoptosis in permeabilized target cells (17, 18) . Finally, the delivery
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of aprotinin (a serine protease inhibitor) to target cells protects them from CTL-induced apoptosis (20) .
Using perforin-deficient mice, several groups have now shown that perforin is crucial for the granule exocytosis mechanism used by both activated CTL and NK cells (3-6, 24, 25) . To better understand the contribution(s) or Gzms in this perforin/Gzm pathway, we recently produced Gzm Bdeficient mice by gene targeting and demonstrated that Gzm B-/-CTL derived from primary mixed lymphocyte cultures have a severe defect in their ability to rapidly induce DNA fragmentation and target cell apoptosis (22) . In the present study, we have investigated the role of Gzm B in NK and lymphokine-activated killer (LAK) cell effector functions by using Na2[5tCr]CrO4 (5tCr) release and 5-[125I]iododeoxyuridine (125IdUrd)-labeled DNA release assays. The release of 5tCr, which labels the cytoplasmic proteins of target cells, reflects the loss of target cell membrane integrity (probably due to pore formation by perforin). The release of 125IIdUrd, which labels the nuclear DNA of target cells, reflects DNA fragmentation and directly correlates with apoptotic death as defined by chromatin condensation and nuclear membrane dissolution of target cells attacked by cytolytic effectors (22, 26) . These studies have revealed that Gzm B-deficient NK and LAK cells both display a severe defect in their ability to rapidly induce apoptosis in susceptible target cells and that Gzm B-/-NK cells have an additional, unexpected, defect in 51Cr release.
MATERIALS AND METHODS
Gzm B-/-Mice. The production of H-2b mice homozygous for a null mutation in the Gzm B gene was previously described (22) .
Isolation of NK Cells. NK cells were activated in vivo by intraperitoneally injecting mice with poly(I)-poly(C) (100 ,tg per mouse in sodium phosphate-buffered saline; Sigma) 20 air/5% CO2. After 3 days, medium was taken from the flasks and nonadherent cells were removed by centrifugation. The medium was put back into the flasks along with fresh complete medium. After 7 more days of culture, cells were harvested by placing the flasks at 4°C for -2 hr. Examination of Cytospin preparations of these LAK cells revealed no differences in the morphology of Gzm B+/+ versus B-/-LAK cells.
Generation of Anti-Gzm B Antiserum. Rabbit antiserum against murine Gzm B was generated by immunizing rabbits (CoCalico, Reamstown, PA) with a synthetic Gzm B peptide (aa 173-185: CESYFKNRYNKTN) conjugated with rabbit serum albumin. The immunized and boosted rabbit sera were tested and shown to react specifically with recombinant Gzm B protein made in Escherichia coli. The IgG fraction of the antiserum that specifically recognized murine Gzm B was purified and further tested for specificity with Con A-and IL-2-activated Gzm B+/+ and B-/-splenocytes (data not shown).
Western Blot Analysis. Total proteins were prepared from 1 x 107 Gzm B+/+ or B-/-LAK cells by sonicating these cells in 200 ,ul of buffer containing 1 M NaCl/50 mM Tris HCl, pH 7.5/0.1% Triton X-100. These extracts were analyzed with a standard Western blotting technique using the anti-Gzm B antiserum described above followed by detection with chemiluminescense (Amersham).
Si Nuclease Protection Analysis. Approximately 10 jig of total cellular RNA derived from NK or LAK cells was used to perform Si nuclease protection analyses using probes specific for murine Gzms A and B, as described (22) .
Flow Cytometry. Flow cytometric analysis was conducted according to the protocol described in our previous study (22) . Fluorescently labeled monoclonal antibodies (PharMingen) specific for CD3, CD4, CD8, NK1.1, and 5E6 were used to stain mononuclear cell suspensions containing poly(I)-poly(C)-activated NK cells. These same antibodies, along with anti-CD16 and antibody to IL-2 receptor ,B chain (anti-IL-2R,B), were used to stain LAK cells.
Production of CTL. One-way mixed lymphocyte cultures were performed exactly as previously described (22) DBA/2 origin) target cells in standard 51Cr or 125IdUrd release assays, essentially as described (22) . For the allogeneic cytotoxicity assay, Gzm B+/+ or B-/-CTL (H-2b-anti-H-2d) were tested against EL-4 (H-2b-expressing lymphoma) or TA-3 (H-2d-expressing lymphoma) target cells, as described (22) . RESULTS Cytotoxicity of NK Cells. NK cells were induced in mice by intraperitoneal injection of poly(I)-poly(C), a potent activator of NK cells. Flow cytometric analysis of these splenocytes revealed no differences between the number of Gzm B+/+ or B-/-cells expressing T-cell markers CD3, CD4, and CD8 and NK cell markers NK1.1 and 5E6 (data not shown), suggesting that Gzm B deficiency does not affect the number of NK precursors or their maturation. Analysis of RNA derived from these poly(I)-poly(C)-induced B+/+ or B-/-splenocytes revealed identical levels of correctly processed Gzm A mRNA; Gzm B mRNA was detected in B+/+ but not B-/-splenocytes, as expected (data not shown). Fig. 1 shows that neither Gzm B+/+ nor Gzm B-/-NK cells (H-2b) lyse the control P815 targets in either a 4-hr 51Cr release assay or a 2-hr 125I-labeled DNA release assay. However, Gzm B+/+ NK cells lysed YAC-1 targets effectively, as indicated by the effector cell dose-dependent release of 51Cr (Fig. 1A ) and 125I-labeled DNA (Fig. 1B) . In contrast, Gzm B-/-NK cells were significantly less efficient in the induction of 51Cr release from YAC-1 targets; these NK cells did not cause any 51Cr release until the E:T ratio was .50:1 (Fig. 1A) (Fig. 3B) . Gzm B1/+ LAK cells were much more efficient in inducing I251-labeled DNA release from YAC-1 targets (60% specific release at an E:T ratio of 10:1) than from P815 targets (12% specific release at an E:T ratio of 10:1). From these results, we conclude that LAK cells also require Gzm B for the rapid induction of DNA fragmentation in target cells.
Late Cytotoxicity in Gzm B-/-Effectors. We further examined the cytotoxicity defect in Gzm B-/-NK cells, LAK cells, and CTL by conducting time-course experiments in which the E:T ratio was fixed at 100:1 for NK, 25:1 for LAK, or 10:1 for CTL (Fig. 4) . No significant difference was observed between the Gzm B+/-and B-/-CTL in mediating 51Cr release from TA3 allotargets (Fig. 4A) [in our prior work (22), we showed that the cytotoxic phenotypes of Gzm B+/-and B+/+ CTL are identical]. In a previous study (22) , we detected a small reduction in the ability of Gzm B-/-CTL to rapidly induce 51Cr release from allotargets; however, with multiple repeat experiments, we have determined that this difference is neither reproducible nor significant. As demonstrated before (22) , 1251-labeled DNA release and apoptosis of TA3 cells attacked by Gzm B-/-CTL are delayed for 4 hr ( The defect in DNA fragmentation in Gzm B-/-NK cells, LAK cells, and CTL is partially compensated by long incubation times of effector and target cells, suggesting the existence of an intact "late" killing pathway(s) in these cells. One of the "late" killing mechanisms may involve the fas pathway. The fas pathway has been shown to be involved in target cell lysis triggered by a CTL hybridoma line (34) . As expected, our analysis of Gzm B-/-CTL has shown no defect in fasmediated cytolytic activity (J.H.R., unpublished observation), implying that fas could represent a redundant mechanism of late cell-mediated cytotoxicity. Another molecule that could participate in the late pathway is Gzm A. Shi and colleagues (17, 18) have shown that rat Gzm A induces DNA fragmentation with slower kinetics than rat Gzm B. Our previous work (22) demonstrated that Gzm A mRNA is normally expressed in Con A/IL-2 activated CTL from Gzm B-/-mice, and the present study reveals that Gzm A mRNA is present at normal levels in NK and LAK cells. Besides Gzm A, other granzymes, such as Gzms C, D, E, F, and/or G, could also potentially be involved in the "late" killing mechanism(s) in CTL, NK, and LAK cells, since expression of these genes is presumably intact in Gzm B-/-animals (22) . The careful analysis of additional granzyme-deficient and/or fas ligand mutant mice should help delineate the key molecules required for this "late" cytolytic pathway and determine the importance of this pathway for the in vivo activities of cytolytic lymphocytes.
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